At The American Epilepsy Society’s annual meeting, held on December 7, 2015 in Philadelphia it expressed opportunistic research concerning the use of hemp extract known as CBD (cannabidiol). CBD is a non-psychoactive extract from the hemp plant. This non-psychoactive extract does not alter one's mood, consciousness or perception. Although this clinical research is anecdotal, the results were positive in most patients with debilitating seizures. Such forms of these treatment-resistant disorders include Lennox-Gastaut Syndrome (LGS) and Dravet Syndrome (DS).
GW Pharmaceutical’s conducted a study to administer Epidiolex (cannabidiol) to 261 patients. Epidiolex is an investigational drug and has not yet been approved for use by the FDA.
The experimental drug was introduced to the patient's current AED (anti-epileptic drugs) treatments and given in gradual amounts while increasing doses during the 12 week study.
Here are their results concluding the 12 week study:
Lead author Orrin Devinsky, M.D., of New York University Langone Medical Center’s Comprehensive Epilepsy Center said:
"We are pleased to report these promising data on significant numbers of children, These data reinforce and support the safety and efficacy we have shared in previous studies. Most importantly it is providing hope to the children and their families who have been living with debilitating seizures. These results are from an uncontrolled study. Further study is needed before results can be confirmed. Randomized controlled studies are now underway to help us better understand the effectiveness of the drug. As a practitioner, I have had families move to Colorado, and many tried multiple different products, As a doctor, I often don’t feel like I know which of many factors is contributing to a patient doing better or worse. We absolutely need rigorous, scientific data on this. We very much look forward to the results from these studies during 2016."
For more than 75 years the AES has provided a forum of medical & scientific members whose goal is the clinical care and research for people with epilepsy. Epilepsy and seizures affect three million Americans of all ages. The AES urges the Federal DEA to review Marijuana as a schedule 1 drug, as do I.
Summary and opinion by Ronald Pires. Check the full article here.
Comments will be approved before showing up.
Baltimore Ravens offensive lineman Eugene Monroe won’t be on the next roster, and it may be for his advocacy for medical marijuana. Monroe’s January recovery from a shoulder injury inspired him to write about marijuana versus opioids, and donate $80,000 to medical marijuana researchers at both Johns Hopkins University and the University of Pennsylvania. His work, he tweeted, was all for his “brothers… the players that make up the team… our future health and wellness.”
Unfortunately, his offseason, offtopic efforts failed to impress the Ravens officials. In the days leading up to his release, attitudes from the organization led Monroe to wonder if his marijuana advocacy was to blame. Interestingly, his original questions were less about the drug, and more about overall NFL healthcare.
It is arguable that reviewing old drug testing policies is going to be a big trend in U.S. companies in the nearest future. If the weed is legal, and the job can be done safely under cannabis influence, why would an employer be concerned about marijuana consumption enough to spend money on drug testing?
Current situation is creating a whole lot of consequences, like people easily cheating on drug tests by adding water to their urine, or other people making money on ‘weed detox sets’ that claim to free your system of cannabis traces in just three days. More than 93% test negative, but employers continue testing. In most cases, we just avoid working for companies that drug test employees.